Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.57 |
| ▸ | FAAH | O00519 | 2/20 | 0.57 |
| ▸ | GPX4 | P36969 | 1/20 | 0.56 |
| ▸ | CDK4 | P11802 | 3/20 | 0.54 |
| ▸ | CCND1 | P24385 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2184755 | 0.86 | KDM4E (0.56) | KDM4ETRPV1FAAHGPX4CDK4 | |
| SCHEMBL8261111 | 0.86 | KDM4E (0.69) | KDM4ETRPV1FAAHGPX4 | |
| SCHEMBL969392 | 0.79 | TRPV1 (0.72) | KDM4ETRPV1FAAHGPX4CDK4 | |
| SCHEMBL17040277 | 0.78 | GPX4 (0.67) | KDM4ETRPV1FAAHGPX4CDK4 | |
| SCHEMBL13203882 | 0.78 | KDM4E (0.62) | KDM4ELMNAMAPTBAZ2B | |
| SCHEMBL2724003 | 0.78 | LMNA (0.80) | KDM4ETRPV1FAAHGPX4CDK4 | |
| SCHEMBL12956428 | 0.78 | KDM4E (0.62) | KDM4EGPX4 | |
| SCHEMBL6784097 | 0.77 | GPX4 (0.49) | KDM4ETRPV1FAAHGPX4CDK4 | |
| SCHEMBL17037430 | 0.76 | GPX4 (0.64) | KDM4ETRPV1FAAHGPX4CDK4 | |
| SCHEMBL4674850 | 0.76 | HDAC3 (0.52) | KDM4ETRPV1FAAHGPX4CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | KDM4E 2860/4885TRPV1 4187/4885FAAH 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.